Didanosine

Generic Name: Didanosine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂N_₄O_₃

CAS Number: 69655-05-6

Unique Ingredient Identifier: K3GDH6OH08

Background: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse tra...

Indication: For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Bioequivalence Study of Didanosine in Children Treated for HIV

Phase 2

Suspended

Conditions: HIV Infections

Interventions: Drug: didanosine

First Posted Date: 2008-04-29

Last Posted Date: 2009-02-09

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 26

Registration Number: NCT00668356

Locations: 🇫🇷
Hopital Necker, Paris, France

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Zidovudine
Drug: Stavudine
Drug: Lamivudine
Drug: Didanosine
Drug: Lopinavir/Ritonavir
Drug: Efavirenz

First Posted Date: 2006-06-21

Last Posted Date: 2013-05-21

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 1771

Registration Number: NCT00342355

Locations: 🇿🇦
Mtubatuba SIckbay, Kwazulu-Natal, South Africa
🇿🇦
Umtata Sickbay, Eastaern Cape, South Africa
🇿🇦
South African Military Health Services (SAMHS), Centurion, South Africa

and more 4 locations

Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir
Drug: Abacavir+Lamivudine
Drug: Didanosine

First Posted Date: 2006-06-20

Last Posted Date: 2015-03-24

Lead Sponsor: Hospital de Granollers

Target Recruit Count: 75

Registration Number: NCT00338390

Locations: 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸
Hospital Sierrallana, Torrelavega, Santander, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain

and more 18 locations

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Phase 4

Completed

Conditions: HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease

First Posted Date: 2005-09-19

Last Posted Date: 2012-04-12

Lead Sponsor: Kirby Institute

Target Recruit Count: 80

Registration Number: NCT00192660

Locations: 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

Phase 3

Completed

Conditions: HIV Infection

First Posted Date: 2005-09-12

Last Posted Date: 2007-07-03

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 100

Registration Number: NCT00158470

Locations: 🇻🇳
Binh Trieu Hospital, Ho Chi Minh City, Vietnam
🇻🇳
Tropical Diseases Hospital, Ho Chi Minh City, Vietnam

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir sulfate
Drug: Didanosine
Drug: Efavirenz
Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2005-02-07

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 377

Registration Number: NCT00102960

Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings

Not Applicable

Completed

Conditions: HIV Infections
Tuberculosis

First Posted Date: 2004-09-21

Last Posted Date: 2010-03-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 592

Registration Number: NCT00091936

Locations: 🇿🇦
King Edward VIII Hospital, Congella, Durban, South Africa
🇿🇦
Prince Cyril Zulu CDC, Congella, Durban, South Africa

Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2004-06-09

Last Posted Date: 2013-09-20

Lead Sponsor: Centro di Riferimento Oncologico - Aviano

Target Recruit Count: 20

Registration Number: NCT00002905

Locations: 🇮🇹
Centro di Riferimento Oncologico - Aviano, Aviano, Italy

Strategies for Delivering Anti-HIV Therapy in South Africa

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2004-04-07

Last Posted Date: 2007-09-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 813

Registration Number: NCT00080522

Locations: 🇿🇦
University of the Witwatersrand/Clinical HIV Research Unit, Johannesburg, Gauteng, South Africa
🇿🇦
University of Cape Town/Masiphumelele, Cape Town, South Peninsula, South Africa

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir
Drug: Didanosine
Drug: Efavirenz
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nevirapine
Drug: Stavudine
Drug: Tenofovir disoproxil fumarate
Drug: Zidovudine/Lamivudine

First Posted Date: 2003-12-17

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3526

Registration Number: NCT00074581

Locations: 🇺🇸
Fenway Community Health Ctr. CRS, Boston, Massachusetts, United States
🇧🇼
Gaborone CRS, Gaborone, Botswana
🇧🇷
Hospital Geral de Nova Iguaçu CRS (HGNI CRS), Nova Iguacu, Rio De Janeiro, Brazil

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy